Stock Investing Guide

Beginners Road To Stock Investment


KEYS TO BEING A SMARTER INVESTOR - -PART 3

11.DON'T OVER LOAD ON COMPANY STOCK


As many employees at Enron and other large bankrupt

companies learned the hard way, loading up your 401(k)
with your employer’s stock can be disastrous. Both your
job and your retirement security are riding on the fortunes
of a single employer and a single industry.
Financial planners typically recommend limiting company
stock to no more than 5 or 10 percent of the account’s
value. But this can be difficult to do if the employer will
only match your plan contributions with company stock
while restricting how soon you might sell the stock
and diversify through other investment options offered.
Consequently, you may need to try to diversify your overall
portfolio through other types of assets you hold outside
your 401(k) plan.

1 2.DON'T CHASE 'HOT' PERFORMANCE

Today’s hot investments are often tomorrow’s cold

turkeys. The most recent glaring example of this was
tech stocks, represented by the NASDAQ stock index. The
NASDAQ returned a record-smashing 85.6 percent in 1999,
but fell nearly 40 percent the following year, and lost
another 21 percent the next year.
The major problem with chasing the current hottest
investments is that by the time most investors discover
that an asset category or specific investment is “hot,” the
investment often has already realized much or most of its
run-up in value. Consequently, investors often get in at
about the time the investment is ready to fall.
Calculations by DALBAR, a consulting firm, show that
stock investors who frequently trade in and out of mutual
funds earned a meager 3.51 percent annually between
1984 and 2003—dramatically below the 12.98 percent
annual average earned by the S&P 500 stock index over
the same period.

13. DON'T IGNORE 'COOL' PERFORMANCE

The opposite of chasing hot investments is ignoring those

suffering through tough times. Real estate investment
trusts, for example, did poorly in 1998 and 1999, but
boomed in 2000 and 2001 when stocks faltered.
Government bonds lost money in 1994, but returned
nearly 14.5 percent the next year.
A time tested way to avoid the problems of ignoring cool
performance and chasing hot performance is to stay
diversified and stick with the asset allocations spelled
out in your investment policy statement.

14. STAY IN THE MARKET

Nervous investors often sit on the sidelines during

down markets until they’re “convinced” the market is
rebounding. But by the time they get up enough nerve to
get back in, they’ve likely missed much of the rebounding
market’s gains, which commonly occur in the early stages
of recovery.
SEI Investments studied 12 bear markets since World War
II. Investors who either stayed in the market through its
bottom, or were fortunate to enter at the bottom, saw the
S&P 500 gain an average of 32.5 percent (not counting
dividends) during the first year of recovery. Investors who
missed even just the first week of recovery saw their gains
that first year slide to 24.3 percent. Those who waited
three months before getting back in gained only 14.8
percent. The secret is time, not timing!

15. START INVESTING EARLY


Remember the famous image of Archimedes moving the

world on the end of a long lever? Investing over time
provides that same kind of leverage. The longer you invest
money (the longer the lever), the more it “works” for you
by growing faster and faster.
For example, invest $10,000 at an eight percent annual
return inside a tax-deferred account, such as an IRA, and
you end up with $21,589 after ten years. Keep the money
in for 20 years and it grows to $46,610. Keep it in for 30
years and the same $10,000 initial investment balloons
to $100,627.



KEYS TO BEING A SMARTER INVESTOR - -PART 2

6. EDUCATE YOURSELF ABOUT INVESTMENTS AND INVESTING


Even if you work with a financial planner or other
investment professionals, you need to have a solid
understanding of how different types of investments
work, their potential returns, their risks and how you
can assemble them in a cohesive portfolio that’s right
for your needs and goals.
Pay particular attention to investment risk. All investments
carry some degree of risk. While stocks in general tend to
perform well over long periods of time, for example, their
short-term risk can be high, as many investors painfully
learned during the market decline of 2000–2002. Risk is
not limited to stocks, either. You can lose money in real
estate, corporate bonds, gold and commodities. This is
why it is important to note that diversification among
different asset classes may help reduce risk.
Even so-called “safe” investments carry some risk. U.S.
Treasury bonds, for example, are federally guaranteed
against loss of principal as long as you hold them until
they mature. Because they are subject to interest-rate
risks like any other type of bond, however, it’s possible
to lose money if you sell them before maturity.
Don’t understand interest-rate risk? If you don’t
understand how a particular investment works, or
the risks that come with it, ask for help before you invest.
Invest a little in education first. Ask your financial planner
or investment professional for resources to help you make
the best decisions.

7. HOLD REALISTIC MARKET EXPECTATIONS

One of the downfalls for many investors during the
booming market of the late 1990s was their belief that
high double-digit returns were normal for stocks. But
historical investment returns reveal otherwise.
According to Ibbotson Associates, large-company
stocks, such as those found on the Dow and the S&P 500,
returned an annual average of 10.4 percent from 1926
through 2006. During the same period, small-company
stocks returned 12.7 percent and long-term government
bonds averaged 5.4 percent.
But these are only averages over many years. In any given
year, you will probably not earn the annual “average”
return. You’ll earn either more or less than the average.
Knowing the historical average returns can keep these
fluctuations in perspective.

8. FOLLOW A DETAILED WRITTEN PLAN

Formally, this is called an investment policy statement.

It’s a road map to keep you on course through good times
and bad, to eliminate investment ideas that don’t fit your
circumstances, and to provide a way to monitor the actual
performance of your investments. This plan is, of course,
subject to changes over the course of your investing
lifetime and should be reviewed periodically.
The plan outlines such things as:
• Investment goals and time horizons
• Minimum average annual return needed
to achieve those goals
• Current income needs from the portfolio,
if any
• Types of investments you will and
won’t include

9. ALLOCATE INVESTMENTS ACCORDING TO GOALS AND NEEDS

How will you divvy up your investment dollars among
various asset categories such as large-company and small company
stocks, international equities, government and
corporate bonds, cash, real estate and other assets?
The answer depends on several factors. Key among them
are your investment goals and your time line for achieving
them. The sooner you’ll need the funds, usually the more
conservative your investments should be.
Also, what other financial resources are available to you?
If Social Security and a good pension will generate most
of your income needs in retirement, you may feel
comfortable with a more aggressive approach to your
investment portfolio. You may opt for a more conservative
approach, however, if your investment portfolio will be
a primary source of retirement income.

10. DIVERSIFY YOUR INVESTMENTS

Too often, individual portfolios invest heavily in a single

type of asset, often to the near exclusion of other types.
A popular choice in recent years has been large-company
U.S. stocks, also called “large-caps.” These stocks
outperformed other major asset categories in 1989 and
from 1995 to 1998. Yet, in all other years between 1965
and 2006, large-caps were outperformed by small company
stocks, international stocks, intermediate
bonds or investment real estate.
Because it’s almost impossible to identify in advance
which asset classes will lead the way during any given
time, it’s wisest to spread dollars among several
investment classes. Research has shown that this
diversification reduces risk while at the same time
maintaining or even improving portfolio performance.
Investors also may want to diversify within broad
categories. Among stocks, for example, they might divide
their money between value and growth stocks, or between
large-cap and small-cap. They may also want to include a
variety of industries or sectors like technology, consumer
goods and health care.



Urbanizing Income in China Gives Us a Quick 17% Gain

Shares of American Oriental Bioengineering Inc (AOB: NASDAQ) are up more than 17% in the past week on news of a strong fourth quarter
. The company posted revenue of $96.3 million – a 68% jump – and net income of $21.7 – up 43% on the quarter.

While pharmaceutical companies here in the U.S. are struggling to keep up, AOB is catching fire. This solid growth is what attracted us to the company in the first place. After almost a full 12 months of holding it, we are still impressed every earnings announcement.


The company recently expanded its capacity and product line. It also has ambitions to reach further into the rural Chinese market. As we noted when we first recommended AOB, rural China is the place to be. Our colleague, Chris Mayer, recently found this chart, which sums up our point:



As you can see, China is currently in a heavy period of urbanization. With this many people moving to major cities, average income will rise. When that happens, we’ll see a large increase in discretionary spending, which means more money for supplements and pharmaceutical products.

AOB is, and will continue to be, the country’s leading pharmaceutical provider as long as they reach as many customers in rural areas now. If they can do that, these customers will stay loyal when they move to the cities and have larger incomes.


We are already seeing this take place, and should continue to see results like these for a while. If you haven’t already, we recommend you buy shares of AOB.


Action to take: Shares of American Oriental Bioengineering Inc (AOB: NASDAQ) remain a buy at current prices.


Finally, a Bull Indicator For Our Silver Play

We just got word that for the first time in many months, the short interest in Coeur d’Alene Mines Corp (CDE:NYSE) is down. That means, the number of people now shorting – or betting on it to fall – is 18% lower than it was two weeks ago.


One of the common complaints on Wall Street last year was the amount of people shorting the banks. Many of those companies blamed the shorters for causing a panic and depressing share prices. We found out they were wrong in that case, but they still have a point: shorting can depress share prices.


This is one of the reasons our shares of Coeur have fallen in value. There’s been a massive short interest since we bought in 2007. These shorts are now finally leaving this trade. They’ve done well over the past year, but now it’s our turn.


Coeur, as we’ve said, is about to start production at its Palmarejo mine this month. You’ll want to be on board when that happens.


Action to take: Shares of Coeur d’Alene Mines Corp (CDE:NYSE) remain a buy at current prices.

1.UNDERSTAND THE DIFFERENCE BETWEEN SAVING AND INVESTING

Saving is for smaller, near-term goals, such as the next

family vacation, a car or a financial emergency. Keep
cash in a savings account, money market or short-term
certificate of deposit where you would have little or no
risk of losing principal and can have immediate access
to your funds.

Investing is for larger, long-term goals—at least five years
away — such as retirement or college. Investing carries risk
such as loss of principal or not earning as much as
anticipated. But wise investing also provides a greater
opportunity for earning a significantly higher rate of return
over the long run than you can earn through savings.


2.PUT THE REST OF YOUR FINANCIAL HOUSE IN ORDER FIRST


Before investing, consider tackling several other household
financial issues. Create a budget, or spending plan, in order
to free up money for regular investing. Pay off expensive
credit cards or other high-interest consumer debt that eat
up valuable investment dollars. Build a cash emergency
fund that includes three to six months of living expenses
and buy the right kinds and amount of insurance to protect
against a financial setback—otherwise, you may be forced
to raid your investment accounts for cash at a time when
the market is down or with costly tax consequences.


3.CLARIFY YOUR GOALS

Smart investing means investing with a specific purpose—
those life goals such as your desired retirement lifestyle or
passing money on to heirs. Investing with purpose makes
it easier to stick to your investment plan and to invest
income you might otherwise spend. Goals should be
realistic, with a specific amount to accumulate by a
reasonable target date. “Retirement” isn’t a goal. What kind
of retirement you want and when you want to retire are.
Write down your goals and discuss them with your family.


4.DON'T JUST GRAB FOR THE HIGHEST RETURN

One of the most misunderstood aspects of investing is
the belief that investing is all about seeking the highest
possible returns. This misperception is why so many
investors got into trouble during the booming stock
market of the late 1990s when they disdained “average”
returns and began chasing the riskiest of stocks. Their
purpose was simply to “make as much money as possible
in the shortest time.” This example illustrates why
investment goals are important. With reasonable, specific
goals, you can make informed, realistic investment
decisions designed to accomplish your financial goals
without taking unnecessary risk. Making decisions based
on these investment goals is what steers you on an even
course between the rocky shores of greed and fear.


5.UNDERSTANDING YOUR OWN RISK TOLERANCE


In addition to understanding the risks of each type of
asset and investment vehicle, you need to understand
how much risk you’re willing to take and which types
of risk worry you the most. Risk tolerance is partly a
function of your investment goals, how much time you
have to invest, other financial resources you have and,
frankly, your “fear factor.” Investments that keep you
awake at night, regardless of how “good” they might be
for your needs, are not the right investments for you.
Accurately gauging your tolerance for risk can be tricky,
however. It’s easy to feel confident when the market is up
and conservative when it is down. A CFP professional can
help you assess where you truly stand. Questions you and
your planner might ask include:
• Are you more concerned about losing
principal or losing purchasing power?
• How much principal are you willing to lose?
• How worried were you about your
investments during the recent market decline?
• Which of your current investments keep you
awake at night?
• Do you track your investments daily
(a possible indication of unease)?
• How diversified is your portfolio?
• What investment vehicles you’ll use, such
as individual securities, mutual funds,
separately managed accounts, or taxable
and tax-favored accounts
• How assets are to be allocated within the
total portfolio
• Rebalancing procedures
• Potential tax consequences
• Estimated risk level of the portfolio
• Updating income needs due to inflation
and medical costs

PETROLEUM PRICES UP.

Oil rose above $48 a barrel on Friday ahead of OPEC's Sunday meeting in Vienna, after two volatile days of trade this week.

The producer group gathers in the Austrian capital this weekend to discuss its output policy and perhaps adjust the 4.2 million barrels per day cut it implemented last September in reaction to the depth and speed of the global financial crisis.

"OPEC has done everything they can to set the market up for some kind of cut to try and push the price a bit higher," said Simon Wardell, director of global oil analysis and forecasting at IHS Global Insight.

"But it might be that what we get in Vienna is talk of implementing full compliance of previous cuts before we get to the next one, to try and give the hard pressed economy of the world a respite," he said

Oil has hovered between $33 and $50 since the beginning of the year after OPEC implemented and began showing compliance to output cuts put in place to arrest its slide off last July's peak above $147 a barrel.

U.S. light crude for April delivery rose 99 cents to $48.02 a barrel by 1220 GMT, having jumped $4.70 on Thursday to settle at $47.03 and erasing the previous two sessions' losses.

London Brent crude rose 61 cents at $45.70.

FURTHER CUTS?

Ahead of its meeting on Sunday, OPEC released a report in Friday showing world oil demand is contracting faster than expected and increasing pressure on prices.

The Organization of the Petroleum Exporting Countries said global demand would fall by 1.01 million bpd on 2009, revising its earlier forecast of a fall by 580,000 bpd.

"With continued economic deterioration and demand erosion as well as the impending low demand season, there is likelihood of renewed pressure on prices," the report said.

Earlier on Friday, the International Energy Agency, which advises 28 industrialized nations on energy policy, said strict adherence to OPEC's September cuts would shrink oil stocks in developed nations, even as it projects further demand contraction, implying OPEC would not lower output curbs on Sunday.

"Our view it that they don't really need to do very much more in terms of new targets," said head of the oil industry and markets division David Fyfe of the Paris-based IEA.

OPEC seaborne oil exports, excluding Angola and Ecuador, will fall to a five-year low in the four weeks to March 28, to 22.76 bpd, down 350,000 bpd, UK consultancy Oil Movements said in its latest weekly estimate on Thursday.



To track how your stocks are doing, you have to look at stock listings. Stock listings are published in just about every newspaper. The listings look confusing at first, since they look like a mixture of numbers, but can be a very useful tool when tracking your stock's progress. The listings are organized into many columns, including the following information:

52 WEEKS HIGH AND LOW:
This field is a good indicator about a stocks volatility. Volatility is an indicator of the riskiness and potential for profit that the stock has. The greater the difference between the high and low, the riskier the stock is for loss and gain.

COMPANY NAME:
This field is usually abbreviated in the listings, and listed alphabetically.

SYMBOL:
This field is a one to five character symbol used as a sort of nickname for the company.


DIVIDEND: This field is listed in currency format, and it is the cash amount of money that the company will pay you each year for each stock.

PERCENT YIELD:
This field is calculated by dividing the dividend by the closing price. It just tells you how much of the price of the stock you will be paid in dividends each year.

PE RATIO:
The price-earnings ratio calculates the relationship between the price of a company's stock, and the annual earnings of a company. It is calculated by dividing the closing price of the stock by the earnings per share of each stock.

VOLUME:
The volume is the amount of stocks that were traded the day before.

HIGH,LOW AND CLOSE:
These are the highest and lowest prices of the stock the day before, and the closing price for the day before. This is an indicator of how much the price of the stock fluctuated throughout the previous day.

NET CHANGE:
This is the change of the price of the stock from the previous day. This gives you an idea whether the price is dropping or rising.

In addition to the stock listings, stock price charts can sometimes offer a better view of how the stock is doing.

The price charts graphically organize the value of the stock over time. The charts can give you information on the company's historical performance, the stock's stability or volatility, the stock's current price relative to the past, and the stock's growth rate.

PATIENCE:

Wait for all the stars to line up! Good things come to those who wait, be it low buy prices or high sell prices. Sometimes if you had only waited, you could have sold higher or bought lower.

Have patience! It's without a doubt one of the golden keys to making money in the stock market. The patient trader has self-control and waits for his indicators to tell him when to enter or exit.

Even if the market "appears" to have ended its rally, if it does not meet certain criteria the trader had previously set for himself, he must wait.

REVERSE PSYCHOLOGY:

If patience is the golden key to trading, then the silver key is doing things opposite from the rest of the market! You want to buy when the average investor is selling and driving the price down.

And when good news is driving a stocks price higher, you want to sell your shares at the over inflated price.

Buying when stocks are falling and selling when they are moving into higher ground is one of the hardest things to learn to do when you first start trading.

We don't have the luxury of holding our stocks for years to help iron out the little highs and lows. We live off the little highs and lows! Buy when there is blood in the streets!

EMOTIONS:

The stock market is very good at playing on your emotions. In order to be a good trader, you must look at the market in a cold, hard way. When the masses are selling in a panic, you must stand fast or step up and buy.

Remember that the market is made up of emotional herds buying and selling in waves. You must be the cold, cunning and calculating wolf looking over the herd for your kill. Don't panic sell and don't buy on hysteria.

MARKET ORDERS:

Don't use them unless you have to. Don't ever place a market order for a stock at the opening of the market, or when a stock is making new ground fast.

Putting in a market order in the first 15 minutes of the market is a sure way of paying the highest possible price for your stock, because as all the built up orders from the previous day go through, it lifts the stock prices for a few minutes.

You can be pretty sure that your order will go off at the high of the day this way. (but keep in mind it's sometimes handy to sell during this time).

STOP LOSSES:

These are almost as bad as market orders. Stop losses are a sure way of selling at a loss.

You can only use them when you are "in the money" and would normally sell your stock, but want to retain a slight possibility that it might continue to go higher.

BUYING LOW:

Sometimes the best way to buy low is to
put in an order for a stock at "a price you'd love to own the stock at." Let's assume for a moment that the stock you want is trading at 100, try putting in an order at 95 and wait it out, what do

you have to lose? You never know when you might hit the low for the day that way. It's far better than putting your order at 99, only to find it crashed past that, filled your order and continued down to 95. You'd be surprised what an effective way this can be to both buy and sell. When you get your "dream" price, it's a great feeling.

SELLING: Selling is actually harder than buying in many ways. Try to decide what price you want to sell your stock at as soon as you buy it, so when that price does come along, you'll be ready to move.

FREE LUNCH: If there is a free lunch in day trading, it's picking stocks that are making new medium trend highs to trade with. That way if you do get in at the wrong point, there's a much better chance that your high buy will turn into the next low buy as the stock moves higher in its overall trend. This is one of the only safety nets you have in day trading, when combined with patience and some extra cash reserves.

IF YOU ARE WRONG: Then you are wrong! Don't try to justify a bad trade by convincing yourself it will turn into a good trade. If you buy on the high side, then sell at break even and buy back in on the low side. Talking yourself into believing that your mistakes are actually wise moves in disguise is very costly. Be professional enough to spot your mistakes and move on.

PROFITS AREN'T AS IMPORTANT AS YOUR CAPITAL: If you miss out on some profits, that's okay, you can always find another stock to buy. However, if you lose a big chunk of your trading money then the game is over. Protecting your trading capital is your number one mission, followed, of course by increasing it.

DON'T GET GREEDY: Greed will make you poor! If you experience an overwhelming emotional urge to take a trade because you are sure to make a killing this time, then you are experiencing greed. Greed and fear drive the markets and for the most part drive the average investor to making mistakes. Sell with good profits, but don't get too greedy. A savvy trader once said, "Pigs get fat, hogs get slaughtered".

BIG SWINGS:

Big moves up are sometimes follow
ed by big moves down and visa versa. Sell on abnormally large moves to the upside and buy on abnormally moves to the down side.

They are generally out of character of the stock and can many times be followed by a "snap back" on the stock. Knowing your stock's trading habits can be very helpful.

HOT STOCKS:


Stocks that are hot move great, but nothing lasts for ever. If you buy a stock for a big, quick gain and find that the stock has "lost its heat," don't allow your money to be dead -- unless you are looking for an investment!

Sell and move on, don't justify your mistakes - it tends to be a costly justification process in the long run. Others in the stock for the hot ride will start to bail out as the stock cools off and looks like it"s not capable of making "hot moves".

JUSTIFICATION IS COSTLY:

Don't hold a losing stock to justify your purchase. If you make an incorrect buy or end up with a stock that is falling when you thought it would climb handle those mistakes quickly.

Do not be tolerant of stocks that are costing you time and money! Get rid of them!

SUDDEN MOVES UP:

Be very careful buying stocks that have just made sudden moves up. Many times they are following very closely with sudden profit taking.

TIME TO BUY:

One of the best times to buy is when a stock is going down on low volume (with no news) as compared to recent increases on higher volume.

This suggests that the selling is lighter and that the holders of the stock that are going to sell have finished selling and the rest are holding.

The sellers of the stocks then may come back into the market when they see the price stabilize. It's also not a bad idea to sell on high volume on the way up, as this usually creates abnormally high prices that cannot be maintained for long.

DAILY VOLUME:

Do not day trade in thinly traded markets, or on stocks that have very low volume. You may find you can't get out of the market as timely as you think.

TRADING TRUISMS ARE LIES:

If it were possible to implement, "Buy low and sell high" or, "Cut your losses and let your profits run" in any meaningful way, then the majority of the people would be making money.

THE SWITCHES:

Your investment method starts losing, so you switch to another, which immediately also starts losing ...

By switching, you open the door to getting the worst results from each method and none of the good and the overall result can be much worse than even the worst system followed faithfully.

THE DIPS:

You can't take advantage of market dips if you are already in the market. It's better to be out of the market more for day trading than in the market.

This will allow you to get in and out with profits fast and be on the sidelines should dips occur. Try to be out of the market more with your trades and in the market more with your investments!




The techniques and the characteristics of the most successful investors are diverse, and there's not a guaranteed formula of success.

Nonetheless, by looking at the mindsets of certain successful investors, we can learn by following 8 of their key traits:

1. REASON:

Arguably the most important characteristic. You need to justify why you hold each company in your portfolio. You must seek out high-quality stocks that are undervalued by the market, and therefore cheap.


2. COMMITMENT:

To exploit your strategy you have to do the research - and keep doing it - including surveying all financial data, online investment resources and company reports. Don't forget that "numbers have no prejudices."

3. DISCIPLINE:

The research process doesn't finish once you've bought a stock.You have to obsessively follow your purchases, to make sure they were sensible.

You'll need discipline, because successful investing is about running your profits and cutting your losses. The stockmarket is a rollercoaster, so you have to ride out the peaks and bottoms.

4. FLEXIBILITY:

If you're going to have rules you need to be able to break them!" The same stocks won't perform well in all markets.

5. Guts:

The best time to buy stocks is the time of "maximum pessimism" - when everyone is selling and fleeing the markets. To do this takes bravery.

6. OPEN MIND:

Seeking out opportunities ignored by other investors prevents prejudices coming between you and an opportunity.

7. PATIENCE:

"Unfashionable stocks" are unlikely to turn around overnight, so you need to know when to hold on.

8. KNOW YOUR LIMITS:

This means accepting you won't be the next Warren Buffett. Professional investors spend their whole day researching companies, have analysts to help them, and can visit companies. That doesn't mean you can't stock-pick successfully as an amateur ...

The best trick is to keep it simple and stick with what you know.



Are you a truly expert investor as you really believe? Do you consider yourself as a well-informed investor who is capable of anticipating and avoiding the majority of the risks that are usually associated with investing? Chances are, you are making many common errors that are costing you a lot of money and may even harm your financial independence and security. Below you can find the two most costly errors investors make with their investment portfolios: 1. Asset Classes and Subclasses How you allocate your portfolio, rather than which investments you select or when you buy or sell them, determines the majority of your investment performance over time.The solution is to allocate your portfolio to many asset classes and subclasses and be careful not to over or under weight any asset class.

Do not mistakenly believe that a properly diversified portfolio is a properly allocated portfolio. Properly allocate your portfolio among the different asset classes first and then diversify the investments within each asset class.

Diversification is the cornerstone of asset allocation and is key to reducing risk, namely company-specific risk. To properly diversify, you should hold sufficient quantities of not-too-similar securities with comparable risk and return trade-off profiles.

2. Inflation

Inflation can destroy the real value of your portfolio over time, thus placing your future financial security at risk.

As a general rule, the longer your investment time horizon, the more you should allocate to equity investments. For shorter investment time horizons, emphasize fixed-income and cash and equivalent investments.

By avoiding these two mistakes -- besides other investing mistakes -- you will be able to design an investment portfolio that will provide the best opportunity to achieve and protect your financial independence and security!



A Blue Chip-Busting Biotech:How One Tiny Drug Developer IsAbout to Take Down Pfizer and Company.


Pharmaceutical behemoth Pfizer currently sports a market cap of $102 billion and annual revenue of $48 billion. Merck, another mammoth drug maker, has a $65 billion market cap and annual revenue of $24 billion. Glaxo SmithKline, with a market cap of $95 billion, generated $22.7 billion in revenue over the past year…
Obviously, these industry leaders know how to make money. Pfizer's annual revenue works out to 47% of its total market cap. The annual revenues for Merck and GSK come out to 36.9% and 23.9% of their market caps, respectively…
This month, we've found a stock that can top the numbers of even the biggest drug giant. It's a penny stock pharma play with a market cap that doesn't even approach $100 million. We don't think it'll stay this way for long, considering the company just signed a commercialization agreement worth more than its entire market capitalization.
You simply won't come across a deeply discounted pharma stock such as this very often. The market has managed to overlook quite a gift…let's take advantage of it.
Grab Your Share of a $31 Billion Market
In 2007, the value of the global pharmaceutical pain relief market was approximately $31 billion. In the United States, two-thirds of the dollar volume of the prescription pain medication market is for drugs used to treat chronic pain, with the remainder going toward drugs used for acute pain.
Javelin Pharmacueticals Inc. (JAV:AMEX) designs products to fulfill unmet and underserved medical needs in the pain-management niche. The company is particularly focused on breakthrough cancer, post-operative, back, orthopedic injury and burn pains. Despite the advances in medicine, the company insists treatments for these types of pain continue to be an underserved medical need.
That's where Javelin's lucrative new contract comes into play…
The company penned an agreement in January worth up to $71 million that includes double-digit royalties on future sales of its new pain drug, Dyloject.
Javelin will receive roughly $12 million in upfront cash payments from European pharmaceutical developer Therabel for the commercialization rights for Dyloject, the flagship product in Javelin's current pipeline. Dyloject is an injectable form of diclofenac, which is a prescription anti-inflammatory drug often prescribed to treat post-operative pain.
Dyloject is undergoing Phase 3 clinical development in the United States - the drug is already available in the United Kingdom. During its pivotal U.K. registration trial, Dyloject's efficacy and safety were shown to be significantly superior to standard intravenous treatments currently marketed in the U.K.
A Faster, Better Treatment
The competition for Dyloject requires dilution and slow infusion into the patient. But Dyloject comes ready to use for immediate IV administration. The drug works faster than its main competitor, and according to a recent study has the potential to save the U.K.'s National Health Service up to $73 per post-operative patient.
Anti-inflammatory drugs such as Dyloject, along with opioids like morphine, are often used post-operatively. They help reduce opioid doses by as much as 50%, thereby decreasing morphine-related side effects on the patient. Some of the opioid side effects reduced by this dose-sparing approach include nausea, vomiting and trouble breathing. Additionally, the less morphine used, the less likely that the patient's body will become dependent upon the addictive drug during recovery.
Dyloject's most significant U.S. competitor in the injectable anti-inflammatory category is ketorolac tromethamine. In January 2006, Javelin announced the results of a Phase 2b U.S. study in which Dyloject showed superior onset of action compared with ketorolac five minutes after intravenous injection.
Bottom line: This drug does what it is supposed to do. And it does it better than all of the leading competitors. That's the ringing endorsement for Dyloject…especially since it's awaiting approval in the U.S.
U.K. Sales and European Agreement Are Signs of Things to Come
Dyloject is already on the market in the United Kingdom, and sales have been growing at an impressive pace. The drug is now on the formularies of 73 hospitals in the U.K., 58 of which were considered gold accounts and 15 silver accounts. In the first nine months of its availability, Dyloject was accepted at 40% of their targeted accounts.
In the most recent quarterly conference call, Javelin CEO Martin Driscoll said that he continues to be impressed with the acceptance of Dyloject in the U.K. This initial trend bodes very well for the pending approval of the drug in Europe and the United States.
The drug has been accepted at 95% of the institutions to which it's been presented. This, Driscoll believes, shows that Dyloject has value to clinicians. It will prove valuable to shareholders, too…
Since Dyloject was introduced to the market, sales of the drug have doubled each quarter. Although that may be a small sample size, it shows the growth potential of the product once it is introduced into a wider market.
Javelin is on schedule to complete its studies on Dyloject and submit applications in late 2009 for approval in the U.S. and European markets. The partnership with Therabel helps Javelin accelerate this process.
Javelin's a Bargain at Current Prices
Javelin has put itself in a fantastic position to succeed. The company currently has $34.6 million in cash and equivalents and no long-term debt whatsoever. Its burn rate during the first three quarters of 2008 was $8.6 million. With $12 million in upfront cash from Therabel, the company is well positioned to wait out approval in the U.S.





Like most of the market, shares of Javelin were slammed over the past year. Even after the partnership with Therabel was announced, the stock didn't bounce much. With drug applications expected in late 2009 and shares are low levels, investors have a great opportunity to get in at a bargain level.
Recently, costs have been higher than expected. Javelin expects these costs will continue to be high in the short term, but will decrease as production increases and the company streamlines supply chain issues. Regulatory approval in the U.S. would be a major step toward scaling this business and reducing operational costs.
A Pipeline Filled to Capacity
Javelin feels that self-medication segment is an area of possible growth. It generally takes 15-20 minutes and sometimes as long as 40 minutes for commercially available oral pain medications to provide any meaningful relief. Javelin says that all three of its product candidates appear to work faster than the oral formulations of currently available prescription pain products. Dyloject has shown to relieve pain in as little as five minutes, a mark that has not been achieved by current injectable anti-inflammatory drugs.
Other shortcomings of presently available pain drugs include poor side effect profiles and requirements for invasive routes of administration, such as intravenous infusion. Due to the current delivery methods, undertreatment and overtreatment often result. Javelin currently has two late-stage drugs aimed at helping resolve these issues.
Rylomine (intranasal morphine) and PMI-150 (intranasal Ketamine) are both in Phase 3 trials in the United States. These candidates are less-invasive routes of administration for self-medications. Both of the drugs have IV-like effects without the invasive nature of IV administration or the need for patient-controlled infusion pumps.
These two product candidates present an opportunity for improved drug therapy both in the hospital setting and other medically supervised settings. The company feels that the economic benefit of nasal administration is very compelling. These products would eliminate the need for the staff and equipment needed to set up an IV. Additionally, by eliminating the IV, the incidences of needle injuries and the potential for transmission of blood-borne viruses are reduced.
The ability of the patient to self-regulate the medicine would provide greater control to the patient and thereby help avoid doses that are higher than necessary.







A Vested Interest in Javelin's Success
CEO Driscoll has shown his confidence in Javelin with his money. In May and June of 2008, Driscoll purchased 50,746 shares of Javelin common stock at a value of $169,598.
He wasn't the only one. In total, Javelin's directors and officers purchased 667,776 shares in 2008. That's more than $1.6 million in company stock.
In 2008, Javelin's leadership made their confidence known with large bets on the company's stock. (Refer to insider table on previous page.)
We like the fact that Javelin's leadership has a significant stake in the company's future. And with shares at their current levels, you have the chance to join them in investing in the potential of these pain-management drugs. 2009 will be a huge year for Javelin. Get in on this bargain now.
Action to take: Buy shares of Javelin Pharmaceuticals Inc. (JAV:AMEX) for $1.75 per share or less.


STAYING IN THE LOOP


Believe it or not, the stock market isn't perfect. It's not the omniscient force so many people think. It's not infallible.
Indeed, the market is driven by people. Buy and sell orders dictate where the market's going at any given time. And more importantly, misapprehensions lead to misaligned prices…that's where money's to be made for investors who are willing to think beyond the confines of Wall Street.
Just look at LoopNet (LOOP:NASDAQ), a victim of the free-falling market that's seen a 51% drop in value over the course of the last year.
LoopNet is the leading commercial real estate marketplace. When a company wants to buy a new office building or an entrepreneur is in need of retail space, they turn to LoopNet because it provides more commercial listings than any other real estate Web site. It also gets more traffic. At more than 910,000 unique visitors monthly, the site has five times more traffic than its closest competitor.
The company has been a Wall Street darling since its initial public offering in 2006, but it's not hard to see why LoopNet's price has fallen so sharply.
Commercial real estate took a massive hit in 2008. In New York City - one of the strongest commercial real estate markets in the country - transactions plunged 61% through October, according to Bloomberg.
Prospects don't look great for 2009 either. Even the most optimistic industry analysts see residential and commercial real estate struggling for the entire year. So why then are we writing to you about a company that helps businesses buy and sell property?
The reason is simple: LoopNet is one of those misunderstood companies.
The Company Wall Street Just Doesn't Understand
Believe it or not, the deteriorating real estate market hasn't taken a huge bite out of the company's ability to make money - LoopNet makes its revenues from the premium subscriptions it sells to companies looking for real estate. The company's more than 88,000 premium subscribers pay less than $100 per month for unfettered access to all of LoopNet's listings.
What's unique about LoopNet is the fact that its subscription rates are relatively resistant to a bad real estate market - after all, is a commercial developer likely to cancel its $100 per month subscription just because the economy's in the gutter? Probably not - it's a tool it needs to conduct its business, even when business is bad.
That idea has translated over to LoopNet's income statement in 2008. In its latest earnings release, on Feb. 11, it reported revenues of $86.1 million, a 22% growth from one year ago.
The notion that LoopNet would be hit hard by a slowdown in commercial real estate has been a misapprehension on the part of Wall Street. The analysts and investment firms miscalculated just how resilient this company is, and now's your chance to profit from their error.
Positioned to Ride out 2009
Right now, LoopNet's financial position puts it in a nice spot to ride out any difficulties it could face in 2009…The company's bank accounts are flush with $66 million in cash, and it's debt free. That means it's got enough money to operate for the next five or six years without any cash coming in the door.
But cash is certainly coming in right now anyway.
In the fourth quarter of 2008, LoopNet reported profits of $18.3 million.



Whether or not commercial real estate markets will rebound in 2009 remains to be seen. There's no question that a better environment for commercial real estate will bring huge benefits for a company like LoopNet. That said, there's also little doubt that LoopNet can continue to thrive in the interim.
Our analysis puts LOOP's value around $15.09 per share - the only question is how long it will take to get there, given Wall Street's inability to realize this company's enormous potential. Even so, we see the stock above $10 in the next year.
Action to take: Buy LoopNet (LOOP:NASDAQ) up to $7.10 per share.

Understanding a company's potential is one of the most important aspects of investing… especially for penny stocks. Without knowing what a company is capable of, you have no chance of ever striking it rich.
Today, we must take a step backwards. It's not something we enjoy, but it's fundamental to smart penny stock investing.
Arrowhead Research Corp (ARWR:NASDAQ) is one of the dream companies you tell your friends about. The firm is the majority shareholder in certain businesses that own major intellectual properties over sciences and breakthrough such as carbon nanotubes, RNAi development, and even stem cell technologies.
The company has exclusive deals with major players in all fields - the most important is Samsung in the LCD field. It also has rights, and ambitions, to technologies that have proven themselves in rehabilitating severed spinal cords.
Unfortunately, the investors were just not there to back Arrowhead up. There's nothing we can do about it. We swung for the fences at a fastball right down the middle of the plate and we missed. These patents and intellectual properties alone are worth our investment. The market just doesn't see it that way.
Lucky insiders of Arrowhead, we have no doubt, will someday be rewarded for their scientific progress. Unfortunately, we are not insiders. NASDAQ has sent a letter announcing that if Arrowhead doesn't bring their shareholder equity above $10 million, then it will be delisted. That's our cue to leave the stage.
While this one hasn't panned out for us the way it should have, we have to acknowledge the potential was right and the risk was justified. It's now time to sell and put our money into opportunities equal in potential and risk. Penny Stock Fortunes aren't made on mediocre gains. They are made by swinging for the fences, even if the rest of the market calls you out from time to time.
We'll keep our eyes peeling to see where these breakthrough intellectual properties go. For now…
Action to take: Sell shares of Arrowhead Research Corp (ARWR:NASDAQ) at market.
Sell Share of Terex Corp.

Terex Corp. (TEX:NYSE) reported a net loss of $421.5 million for the fourth quarter due to a one-time charge of impairment to goodwill. This quarter sank the company's entire fiscal year 2008, leaving it with a net gain of only $71.9 million.
With the shock of the impairment, shareholders are selling like wildfire. Shares fell 31% on the day of the announcement.
It's time for us to get out too - but not because of the one-time write-down…
Terex is, and will stay, an industry leader. But after hearing the CEO spout about increased competition, lowered margins and long-term recession problems, it's clear we are on a different page.
There will be plenty of money to be made in the heavy machinery needed to build infrastructure. Unfortunately, Terex isn't going to benefit as much as it should. It's clear the company is cutting back…
The best businesses will look at an opportunity such as this stimulus bill and take advantage of it. Terex's older brother Caterpillar is doing just that. President Obama said, "The CEO of Caterpillar said that if this American Recovery and Reinvestment Plan is passed, his company would be able to rehire some of the employees they've been forced to lay off."
That's a good sign. But Caterpillar is too big for us - and not exactly cheap at the moment. While we are selling one of our favorites, Terex, we will be looking for other ways to get into this coming infrastructure boom.
Action to take: Sell shares of Terex Corp. (TEX:NYSE) at market.
Sell Shares of AudioCodes
Last week, AudioCodes Ltd. (AUDC: NASDAQ) became one of the newest victims of the recession, missing its already-lowered estimates for the fourth quarter last week. Guidance isn't looking any better, either…
The $38.8 million AudioCodes posted in the fourth quarter was almost 10% less than the company brought in a year earlier.
What's even more distressing is how the bankruptcy situation with Nortel - the company's largest customer - is affecting AudioCodes' top line.
As of right now, our timeframe for recovery for this stock has increased dramatically. We feel that it's not worth holding on to this position any longer, instead using our capital for more promising picks.
Action to take: Sell shares of AudioCodes (AUDC: NASDAQ) at current prices.
Sell SOAP for Double-Digit Gains
Close out your position in Soapstone Networks (SOAP:NASDAQ). In light of another quarter of waiting for the company's PNC technology to be deployed on a wide scale - and translated into earnings - we've decided to book the double-digit gains we've made since recommending the stock on Nov. 20, to avoid the volatility we're seeing in the small-cap market right now.
Gains have been hard earned in 2009, but we've been able to capitalize so far over the last several months. Congratulations on your well-deserved gains on this position.

Action to Take: Sell shares of Soapstone Networks (SOAP:NASDAQ) for 20% gains.




Subscribe to: Posts (Atom)